Bugajski J, Gadek-Michalska A, Borycz J, Bugajski A J
Department of Physiology, Polish Academy of Sciences, Kraków, Poland.
J Physiol Pharmacol. 1993 Sep;44(3):303-12.
Involvement of central histaminergic mechanisms in stimulation of the hypothalamic-pituitary-adrenal (HPA) axis by clonidine was investigated in conscious rats. Clonidine as well as adrenergic and histamine receptor antagonists were administered intracerebroventricularly (icv), the antagonists always 15 min prior to clonidine, and 1 h later the trunk blood was collected for corticosterone determination. alpha-Fluoromethylhistidine (alpha-FMH), a neuronal histamine synthesis inhibitor, was given ip 2 h before clonidine. Immediately after decapitation, brains were exposed and hypothalami were isolated on ice and frozen for further spectrofluorimetric histamine determination. The clonidine-induced increase in the serum corticosterone level was considerably, but not totally, reduced by icv or ip pretreatment with yohimbine, an alpha 2-adrenergic receptor antagonist. The rise in the corticosterone level induced by clonidine was significantly diminished by mepyramine, a histamine H1-receptor antagonist, and moderately lowered by cimetidine, a histamine H2-receptor antagonist. Clonidine significantly augmented the histamine content in the hypothalamus and rest of the brain. The clonidine-induced increase in hypothalamic histamine might be the cause of an increased corticosterone secretion via stimulation of central H1-histamine receptors. On the other hand, alpha-FMH injected 2 h before clonidine considerably diminished both the histamine content in the hypothalamus and the corticosterone secretion induced by clonidine. These results indicate that clonidine given centrally stimulates the HPA activity via not only alpha-adrenergic but also histaminergic mechanisms. Clonidine augments the hypothalamic histamine which, in turn, stimulates the corticosterone secretion, predominantly via histamine H1-receptors. Neuronal histamine is considerably involved in the stimulatory action of clonidine since inhibition of the neuronal histamine synthesis by alpha-FMH significantly depresses the corticosterone response to clonidine.
在清醒大鼠中研究了中枢组胺能机制在可乐定刺激下丘脑-垂体-肾上腺(HPA)轴中的作用。将可乐定以及肾上腺素能和组胺受体拮抗剂经脑室注射(icv),拮抗剂总是在可乐定前15分钟给药,1小时后采集躯干血用于测定皮质酮。在可乐定前2小时腹腔注射α-氟甲基组氨酸(α-FMH),一种神经元组胺合成抑制剂。断头后立即暴露大脑,在冰上分离下丘脑并冷冻以进一步用荧光分光光度法测定组胺。α2-肾上腺素能受体拮抗剂育亨宾经icv或腹腔注射预处理可使可乐定诱导的血清皮质酮水平升高显著降低,但未完全消除。组胺H1受体拮抗剂美吡拉敏可显著降低可乐定诱导的皮质酮水平升高,组胺H2受体拮抗剂西咪替丁可使其适度降低。可乐定可显著增加下丘脑和大脑其他部位的组胺含量。可乐定诱导的下丘脑组胺增加可能是通过刺激中枢H1组胺受体导致皮质酮分泌增加的原因。另一方面,在可乐定前2小时注射α-FMH可显著降低下丘脑组胺含量以及可乐定诱导的皮质酮分泌。这些结果表明,中枢给予可乐定不仅通过α-肾上腺素能机制,还通过组胺能机制刺激HPA活性。可乐定增加下丘脑组胺,进而刺激皮质酮分泌,主要通过组胺H1受体。神经元组胺在可乐定的刺激作用中起重要作用,因为α-FMH抑制神经元组胺合成可显著降低对可乐定的皮质酮反应。